HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Andersson, N. Articles by Ohlsson, C. Search for Related Content PubMed PubMed Citation Articles by Andersson, N. Articles by Ohlsson, C.

¹ Center for Bone Research at the Sahlgrenska Academy, Division of Endocrinology, Department of Internal Medicine, Göteborg University, Gröna stråket 8 SE-413 45 Göteborg, Sweden
² Department of Rheumatology and Inflammation Research at the Sahlgrenska Academy, Göteborg University, Guldhedsgatan 10, SE-413 46 Göteborg, Sweden
³ Department of Physiology, Göteborg University, Medicinaregatan 9, Box 434 SE-405 30 Göteborg, Sweden
⁴ Department of Pharmacology, Göteborg University, Medicinaregatan 9, Box 434 SE-405 30 Göteborg, Sweden

(Requests for offprints should be addressed to N Andersson; Email: niklas.andersson{at}medic.gu.se)

^* N Andersson and U Islander contributed equally to this work

It is generally believed that estrogens exert their bone sparing effects directly on the cells within the bone compartment. The aim of the present study was to investigate if central mechanisms might be involved in the bone sparing effect of estrogens. The dose–response of central (i.c.v) 17ß-estradiol (E2) administration was compared with that of peripheral (s.c.) administration in ovariectomized (ovx) mice. The dose–response curves for central and peripheral E2 administration did not differ for any of the studied estrogen-responsive tissues, indicating that these effects were mainly peripheral. In addition, ovx mice were treated with E2 and/or the peripheral estrogen receptor antagonist ICI 182,780. ICI 182,780 attenuated most of the estrogenic response regarding uterus weight, retroperitoneal fat weight, cortical BMC and trabecular bone mineral content (P<0.05). These findings support the notion that the primary target tissue that mediates the effect of E2 on bone is peripheral and not central.

This article has been cited by other articles:

				P. D. Alfinito, X. Chen, J. Atherton, S. Cosmi, and D. C. Deecher ICI 182,780 Penetrates Brain and Hypothalamic Tissue and Has Functional Effects in the Brain after Systemic Dosing Endocrinology, October 1, 2008; 149(10): 5219 - 5226. [Abstract] [Full Text] [PDF]